NCT04779177View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics of Lumateperone in Pediatric Patients With Schizophrenia or Schizoaffective Disorder

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

March 12, 2021

Primary Completion Date

July 30, 2022

Study Completion Date

July 30, 2022

Conditions
SchizophreniaPediatric
Interventions
DRUG

Lumateperone 42 mg

Lumateperone 42 mg, oral administration

DRUG

Lumateperone 28 mg

Lumateperone 28 mg, oral administration

Trial Locations (3)

30030

Clinical Site, Decatur

30331

Clinical Site, Atlanta

33024

Clinical Site, Hollywood

Sponsors
All Listed Sponsors
lead

Intra-Cellular Therapies, Inc.

INDUSTRY

NCT04779177 - Safety, Tolerability, and Pharmacokinetics of Lumateperone in Pediatric Patients With Schizophrenia or Schizoaffective Disorder | Biotech Hunter | Biotech Hunter